Available EXPANDED_ACCESS NCT04914247

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Sponsor: Actelion

Conditions Non-healing Wound Thromboangiitis Obliterans

Interventions Selexipag

Updated 15 times since 2021 Last updated: Jan 15, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Non-healing Wound and Thromboangiitis Obliterans, this trial is ongoing. The trial is conducted by Actelion and has accumulated 15 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

15 versions recorded

Feb 2026 — Present [monthly]

Available
Feb 2026 — Present [monthly]

Available
Jan 2026 — Feb 2026 [monthly]

Available
Jan 2026 — Present [monthly]

Available
Nov 2025 — Jan 2026 [monthly]

Available

▶ Show 10 earlier versions

Jun 2025 — Nov 2025 [monthly]

Available
May 2025 — Jun 2025 [monthly]

Available
Feb 2025 — May 2025 [monthly]

Available
Jan 2025 — Feb 2025 [monthly]

Available
Sep 2024 — Jan 2025 [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Mar 2024 — Jul 2024 [monthly]

Available
Sep 2023 — Mar 2024 [monthly]

Available
Sep 2022 — Sep 2023 [monthly]

Available
Sep 2021 — Sep 2022 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Actelion

Data source: Actelion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.